![全球首款siRNA药物已成“弃子”,上市才五年,就被里外嫌弃,siRNA龙头的下一步怎么走……](https://www.drugtimes.cn/wp-content/themes/justnews/themer/assets/images/lazy.png)
![“PD-1+TIGIT”全方位打不过化疗?TIGIT,年度最神奇靶点……](https://www.drugtimes.cn/wp-content/themes/justnews/themer/assets/images/lazy.png)
TIGIT单抗的又一次失败记录
![“PD-1+TIGIT”全方位打不过化疗?TIGIT,年度最神奇靶点……](https://www.drugtimes.cn/wp-content/themes/justnews/themer/assets/images/lazy.png)
图片来源:默沙东官网
![“PD-1+TIGIT”全方位打不过化疗?TIGIT,年度最神奇靶点……](https://www.drugtimes.cn/wp-content/themes/justnews/themer/assets/images/lazy.png)
图片来源:默沙东官网
![“PD-1+TIGIT”全方位打不过化疗?TIGIT,年度最神奇靶点……](https://www.drugtimes.cn/wp-content/themes/justnews/themer/assets/images/lazy.png)
理论与现实的差距
![“PD-1+TIGIT”全方位打不过化疗?TIGIT,年度最神奇靶点……](https://www.drugtimes.cn/wp-content/themes/justnews/themer/assets/images/lazy.png)
图片来源:基因泰克官网
![“PD-1+TIGIT”全方位打不过化疗?TIGIT,年度最神奇靶点……](https://www.drugtimes.cn/wp-content/themes/justnews/themer/assets/images/lazy.png)
图片来源:基因泰克官网
![“PD-1+TIGIT”全方位打不过化疗?TIGIT,年度最神奇靶点……](https://www.drugtimes.cn/wp-content/themes/justnews/themer/assets/images/lazy.png)
小结
篇幅有限,补一个快讯。
参考资料
-
Merck Announces KEYLYNK-008 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus LYNPARZA® (olaparib) for Patients With Metastatic Squamous Non-Small Cell Lung Cancer to Stop for Futility – Merck.com
-
Merck Announces Findings from Phase 2 KeyVibe-002 Trial Evaluating an Investigational Coformulation of Vibostolimab and Pembrolizumab in Previously Treated Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC) – Merck.com
封面图来源:Pixabay
![“PD-1+TIGIT”全方位打不过化疗?TIGIT,年度最神奇靶点……](https://www.drugtimes.cn/wp-content/themes/justnews/themer/assets/images/lazy.png)
![“PD-1+TIGIT”全方位打不过化疗?TIGIT,年度最神奇靶点……](https://www.drugtimes.cn/wp-content/themes/justnews/themer/assets/images/lazy.png)
![“PD-1+TIGIT”全方位打不过化疗?TIGIT,年度最神奇靶点……](https://www.drugtimes.cn/wp-content/themes/justnews/themer/assets/images/lazy.png)
![“PD-1+TIGIT”全方位打不过化疗?TIGIT,年度最神奇靶点……](https://www.drugtimes.cn/wp-content/themes/justnews/themer/assets/images/lazy.png)
本篇文章来源于微信公众号: 药时代
发布者:haitao.zhao,转载请首先联系contact@drugtimes.cn获得授权